H.C. Wainwright analyst Robert Burns raised the firm’s price target on Exelixis (EXEL) to $52 from $49 and keeps a Buy rating on the shares after the company announced a strategic collaboration with Natera (NTRA). The firm believes the key value driver for the near- to medium-term will be sentiment on the commercial future of zanzalintinib across various tumor types.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis downgraded to Equal Weight from Overweight at Morgan Stanley
- Exelixis, Natera announce collaboration on STELLAR-316 trial
- Exelixis downgraded to Underperform from Neutral at BofA
- Klaviyo, Wingstop among Stephens Best Ideas for 2026
- Exelixis and Merck Advance LITESPARK-033: A New Kidney Cancer Combo With High-Stakes Market Potential